Gilead Sciences Inc
GILD:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 53.33 | 0.00 0.00% | 0.00% | 12,077 | 13.8M |
Market data is delayed by at least 20 minutes.
Latest News Headlines for Gilead Sciences Inc
Gilead Sciences Supports HarborPath's HIV/AIDS Medication Assistance Pilot Program
HarborPath, an organization which provides a single point of access to HIV/AIDS medications through patient assistance programs, welcomes Gilead Sciences as a participating company. Gilead joins Merck and ViiV Healthcare as the third pharmaceutical company to support HarborPath since its launch in July 2012.
Data from Phase 3 studies of Gilead's sofosbuvir for hepatitis C to be presented at 48th Annual EASL Meeting; Findings published online today in The New England Journal of Medicine
Gilead Sciences, Inc.
(Nasdaq: GILD) today announced that detailed results from four Phase 3
clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating
sofosbuvir, the company's investigational once-daily nucleotide NS5B
inhibitor for the treatment of chronic hepatitis C virus (HCV)
infection, will be presented this week in oral sessions at the 48th
Annual Meeting of the European Association for the Study of the Liver
(International Liver Congress 2013) in Amsterdam, The Netherlands. In
addition, detailed results from the four clinical studies have also
been published online in two papers, ahead of print, in The New England Journal of Medicine (NEJM).
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $54.43
View more recent headlinesShares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $53.86 and have already reached the first level of resistance at $54.43. Should the shares continue to rise, the resistance pivots of $54.81 and $55.76 will be of interest.
Company Background
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 0.00 | Previous Close 53.33 |
Day High 0.00 | Day Low 0.00 |
52wk High/Date 55.16 / 4/23/2013 | 52wk Low/Date 24.12 / 6/5/2012 |
% off 52wk High -3.32% | % off 52wk Low 121.10% |
Beta (5 Yr) 0.5 | Market Capitalization 81.3B |
Shares Outstanding 1.5B | Volatility Avg 27.83 |
EPS(TTM) 1.36 | P/E Ratio 39.3x |
Dividend Announcement -- | Dividend Yield 0.00% |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 4/23/2013 4:00 PM ET | |
GILD Gilead Sciences Inc vs. Peers
| Peers | |
|---|---|
GILD Gilead Sciences Inc | 45.21% |
Abbott Laboratories | 18.73% |
Merck & Co., Inc. | 18.78% |
Pfizer Inc. | 23.93% |
GILD Gilead Sciences Inc | 0.00% |
Abbott Laboratories | 1.50% |
Merck & Co., Inc. | 3.54% |
Pfizer Inc. | 3.09% |
GILD Gilead Sciences Inc | 0.00% |
Abbott Laboratories | 0.00% |
Merck & Co., Inc. | 0.00% |
Pfizer Inc. | 0.00% |